Prof. Dr. Emma Geertruida Elisabeth De Vries

• 1977
  MD, University of Groningen.
  
  

• 1977 – 1982
  Training in Internal Medicine, UMC Groningen, the Netherlands.
  
  

• 1982
  PhD thesis: Clinical and laboratory aspects of acute leukaemia.
  
  

• 1982 – 1983
  Research fellow (1 year), Department of Medical Oncology, City of Hope National Medical Center, Duarte, California.
  
  

• Since 1983
  Senior staff member, Department of Medical Oncology, UMC Groningen, the Netherlands.
  
  

• 1983 – 1989
  Assistant Professor, Department of Medical Oncology, UMC Groningen, the Netherlands.
  
  

• 1989 – 1997
  Associate Professor, Department of Medical Oncology, UMC Groningen, the Netherlands.
  
  

• Since 1997
  Professor of Medical Oncology, University of Groningen, and Head of the Department of Medical Oncology, UMC Groningen, the Netherlands.
  
  

• 2010
  Sept-Dec, Harvard Medical School, Dana Farber Cancer Center, Boston, MA, USA
  
  

• Yao YC, Shah MH, Ito T, Bohas CL, Wolin EM, van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl J Med. 2011;364:514-23.

• Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Warnders FJ, Brouwers AH, de Jong JR, Price PM, Hollema H, Hospers GA, Elsinga PH, Hesselink JW, Gietema JA, de Vries EG. VEGF-PET imaging is a non-invasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res. 2011;71:143-53.

• de Vries EG, de Jong S. Exploiting the apoptotic route for cancer treatment: a single hit will rarely result in a home run. J Clin Oncol. 2008;26:5151-3.

• Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL, de Vries EG. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26:1489-95.

• Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, Nooij MA, Voest E, Hupperets P, TenVergert EM, van Tinteren H, Willemse PH, Mourits MJ, Aaronson NK, Post WJ, de Vries EG. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. J Clin Oncol. 2007;25:5403-9.

• Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728-34.

• Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-82.

• Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, van der Graaf WT, TenVergert EM, van Tinteren H, de Vries EG. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol. 2005;23:8296-304.

• Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EG. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol. 2005;23:5188-97.

• Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG; Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003;349:7-16.

• The American Womens Club of the Hague Grant; Pink Gala, Molecular imaging in breast cancer.

• Pink Ribbon Grant 2008: VEGF imaging for early breast cancer detection.

• Pink Ribbon Grant 2008: Improvement of psycho-social care for breast cancer patients.

• Dutch Cancer Society grant RUG 2009: Molecular imaging as biomarker of HSP90 inhibition pharmacodynamics in breast cancer.

• CTMM (Center for Translational and Molecular Medicine) grant 2009: Mammary Carcinoma Molecular Imaging for Diagnosis and Therapeutics (MAMMOTH), PI: EGE de Vries, UMCG, in collaboration with UMCU, VUMc, TUe, Philips, Roche, BG Medicine & small biotech companies.

• Dutch Cancer Society 2010 fellowship: In vivo analysis of IGF-1R, ER and VEGF expression in trastuzumab resistant breast cancer before and after drug intervention. for AGT Terwisscha van Scheltinga.

• Dutch Cancer Society RUG 2009-4529: FES-PET as a predictive biomarker for response to estrogen therapy in metastatic breast cancer patients.

• Royal Academy of Science (KNAW) professorship.

• ESMO Translational Research Fellowship 2010, K Tamas, Budapest, Hungary. Medical oncologist: Tumor microenvironment with focus on the role of PIGF and colon cancer.

• European Research Council (ERC) Advanced Investigator Grant 2011: OnQview: Non-Radioactive Molecular Imaging-Driven Drug Development in Oncology.

• Dutch Society of Clinical Pharmacology

• Dutch Society of Oncology

• Dutch Society of Internists

• Dutch Society of Medical Oncology

• American Society of Clinical Oncology

• American Association for Cancer Research

• European Society of Medical Oncology

• Patient Care: Certified for Internal Medicine, Medical Oncology and Clinical Pharmacology.

• Participates in all aspects of clinical care in the Department of Medical Oncology: outpatients, clinic, and consultations.

• Participates in training of internists and medical oncologists.

• Coordinates clinical studies.

Soft Skills

• 2 daughters, Josée (1984) and Esther (1986)

You can only see the contact information of the academics in the database if you are a registered user of AcademiaNet.
Please register here